Form 4: Assembly Biosciences Director Receives Stock Option Grant

Assembly Biosciences Director Lisa Johnson-Pratt was granted 3,500 stock options with an exercise price of $15.81, vesting by June 2026.

Summary

• Lisa Johnson-Pratt, a Director of Assembly Biosciences, Inc. (ASMB), acquired 3,500 stock options.
• The stock options have an exercise price of $15.81 per share.
• The transaction date for the grant was June 5, 2025.
• The options are scheduled to vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on continuous service.
• The expiration date for these stock options is June 5, 2035.
• Following this reported transaction, Ms. Johnson-Pratt beneficially owns 3,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that generally aligns the director's interests with shareholder value, which is viewed as a positive for corporate governance. However, as a routine disclosure, it does not significantly alter the company's fundamental outlook or financial position, leading to a slightly positive but largely neutral sentiment.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance and value creation.
• The options have a 10-year expiration period (until June 5, 2035), providing a substantial long-term incentive for the director.

Future Outlook

The granted stock options are scheduled to vest upon the earlier of June 5, 2026, or the date of Assembly Biosciences' 2026 annual meeting of stockholders, provided continuous service is maintained.

Industry Context

The grant of stock options to directors is a common and standard practice within the biotechnology and pharmaceutical industries. This compensation method is widely used to attract, retain, and incentivize board members by aligning their financial interests directly with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• This Form 4 filing reports a routine insider transaction, specifically a stock option grant, which is a standard component of director compensation across various industries, including biotechnology.
• Without specific details on Assembly Biosciences' overall director compensation philosophy or comparable compensation packages from similar-sized biotech companies, a detailed quantitative comparison to industry standards for the size or value of this specific grant is not feasible based solely on this document.

Stakeholder Impact

• Shareholders: The grant of options is intended to align the director's incentives with the creation of long-term shareholder value, potentially benefiting shareholders through improved governance and strategic oversight.

Next Steps

• The granted stock options will vest upon the earlier of June 5, 2026, or the date of Assembly Biosciences' 2026 annual meeting of stockholders, contingent on Lisa Johnson-Pratt's continuous service.

Key Dates

Keywords

Assembly Biosciences, ASMB, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, SEC Filing, Lisa Johnson-Pratt